Family · Pharmaceutical analytical standards
Siponimod
A selective modulator of the sphingosine-1-phosphate receptors S1P1 and S1P5: it keeps lymphocytes in the lymph nodes, stopping them from reaching the nervous system. Approved in 2019 in the United States and then in Europe for active secondary progressive multiple sclerosis. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Before starting it, a genetic test of the CYP2C9 gene, the enzyme that breaks it down, is required: it is one of the medicines where the patient's genetic profile guides treatment.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
